Skip to main content

RTW Investments — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

107
Companies
$11.5B
Total invested
$139.0M
Avg. check
14
Industries
Biotechnology 22Health Care 16Therapeutics 12Pharmaceutical 8Life Science 6Biopharma 5+8 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 107
Dianthus Therapeutics
March 2026

Dianthus Therapeutics is a biotech company developing new treatments for serious autoimmune diseases using a more targeted approach.

Biopharma · Waltham$719.0M Post-IPO Equity
2seventy bio
February 2023

2seventy bio is an immuno-oncology cell therapy company that discovers and develops cancer therapies.

Biotechnology · Cambridge$125.0M Post-IPO Equity
Roivant Sciences
February 2023

Roivant Sciences is a biopharmaceutical company focused on the development of medicines and healthcare technologies to patients.

Biopharma · New York$230.0M Post-IPO Equity
Magnolia Medical Technologies
February 2022

Magnolia Medical Technologies is a device development company that focuses on improving the accuracy of diagnostic blood culture tests.

Health Care · Seattle$46.0M Private Equity
Kailera Therapeutics
October 2025

Kailera Therapeutics develops next-generation injectable and oral therapies for chronic weight management.

Biotechnology · Waltham$600.0M Series B
Ensoma
September 2025

Ensomaa is a genomic medicine company that develops on one-time in vivo treatments for immuno-oncology and other therapeutic applications.

Biotechnology · Boston$53.0M Venture - Series Unknown
Numab
January 2025

Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.

Biopharma · Wadenswil$54.9M Series C
Santa Ana Bio
June 2024

Santa Ana Bio is a biotechnology company focusing on precision immunology for autoimmune and inflammatory diseases.

Biotechnology · Alameda$125.0M Series B
Basking Biosciences
January 2024

Basking Biosciences is to commercialize technology developed at Duke and Ohio State Universities.

Biotechnology · Durham$55.0M Series A
Kyverna Therapeutics
August 2023

Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases.

Biotechnology · Berkeley$60.0M Series B
Abdera Therapeutics
April 2023

Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers.

Biotechnology · Vancouver$142.0M Series B
Alesta Therapeutics
January 2025

Alesta Therapeutics focused on translating novel targets in the chronic stress response pathways into new therapeutic.

Biotechnology · Leiden$67.0M Series A
Crescent Biopharma
December 2025

Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines.

Biotechnology · Rockville$185.0M Post-IPO Equity
Third Harmonic Bio
January 2025

Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, and oral kit inhibitor.

Biotechnology · Cambridge$3.9M Post-IPO Equity
Ottimo Pharma
December 2024

Ottimo Pharma develops innovative cancer therapies using PD1-VEGFR2 antibodies.

Biotechnology · Sandwich$140.0M Series A
Yarrow
December 2025

Yarrow is developing a first-in-class antibody targeting TSHR for the treatment of Graves’ disease and thyroid eye disease.

Business Intelligence · New York$200.0M Venture - Series Unknown
Kalaris Therapeutics (formerly AlloVir)
December 2025

AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases.

Biotechnology · Houston$50.0M Post-IPO Equity
Belite Bio
December 2025

Belite Bio is a clinical stage biopharmaceutical drug development company.

Biotechnology · San Diego$350.0M Post-IPO Equity
Tenaya Therapeutics
December 2025

Tenaya Therapeutics a clinical-stage biotechnology company that develops novel therapies to treat heart diseases.

Biopharma · San Francisco$60.0M Post-IPO Equity
Rocket Pharmaceuticals
December 2024

Rocket Pharmaceuticals is a biotech company that develops a pipeline of genetic therapies for rare childhood disorders.

Biotechnology · Cranbury$165.0M Post-IPO Equity
Mirador Therapeutics
January 2026

Mirador Therapeutics develops precision medicines for immune-mediated diseases.

Biotechnology · San Diego$250.0M Series B
Verastem Oncology
November 2025

Verastem is a biopharmaceutical company developing new medicines to improve the lives of patients with RAS/MAPK pathway-driven cancers.

Biopharma · Needham$90.0M Post-IPO Equity
Biomea Fusion
October 2025

Biomea Fusion is a precision oncology company developing novel small molecules that target aggressive forms of cancer.

Biotechnology · Redwood City$25.0M Post-IPO Equity
SAB Biotherapeutics
March 2026

SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.

Biotechnology · Sioux Falls$85.0M Post Ipo Equity

Where RTW Investments invests

Biotechnology22
Health Care16
Therapeutics12
Pharmaceutical8
Life Science6
Biopharma5

About RTW Investments's portfolio

How many companies has RTW Investments invested in?

RTW Investments has invested in 107 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does RTW Investments invest in?

RTW Investments's top investment sectors include Biotechnology, Health Care, Therapeutics, Pharmaceutical, Life Science. The firm invests across 14 different industry categories.

What is RTW Investments's largest investment?

Among tracked funding rounds, Dianthus Therapeutics received $719.0M in a Post-IPO Equity round. RTW Investments's total known invested capital is $11.5B.

What is the average investment size for RTW Investments?

RTW Investments's average investment size is $139.0M across its portfolio of 107 companies.

What are RTW Investments's most recent investments?

Recent RTW Investments portfolio additions include Dianthus Therapeutics, 2seventy bio, Roivant Sciences, Magnolia Medical Technologies, Kailera Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 107 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →